• The stock price of Moderna (NASDAQ: MRNA) fell by 6.7% in the most recent trading session. This is why.

The stock price of Moderna (NASDAQ: MRNA) fell by 6.7% in the most recent trading session.

Why: Q4 results

Q4 results: Moderna reported a Q4 EPS of $3.61, which was $1.09 lower than a consensus of $4.70. And the revenue for the quarter was $5.1 billion compared to a consensus of $5.05 billion.

KEY QUOTES:

“2022 was another impressive year for Moderna, with over $19 billion in revenue and significant clinical breakthroughs across our portfolio. We continue to provide our Omicron-targeting bivalent vaccines worldwide, with the latest real-world evidence highlighting the continued protection of our vaccines against hospitalization and death. Our infectious disease platform continues to progress with positive Phase 3 data in RSV for older adults. We are investing to scale Phase 3 manufacturing for personalized cancer vaccines so that we can run several Phase 3 studies simultaneously. With planned R&D investments of $4.5 billion for the year, I am excited about the new medicines we believe we will bring to patients in the coming few years.”

“Juan has played a tremendous role since joining Moderna in 2017. Juan served as Chief Technical Operations and Quality Officer and led our manufacturing from an early-stage clinical development company to a commercial company. In 2020 and 2021, Juan did a historic job with his team to scale Moderna for a global commercial launch, during a pandemic. It is unbelievable that he led the team from having made less than 100,000 doses across our entire portfolio in 2019 to more than 800 million doses in 2021 of our COVID-19 vaccine globally, all during a pandemic. Very few manufacturing leaders could have led such an achievement during such a challenging time. We, and the hundreds of millions of people across the globe who received the Moderna COVID-19 vaccine, owe Juan our gratitude.”

— Stéphane Bancel, Chief Executive Officer of Moderna